John P. Overington
John P. Overington
CIO, Medicines Discovery Catapult
Verified email at md.catapult.org.uk - Homepage
Title
Cited by
Cited by
Year
How many drug targets are there?
JP Overington, B Al-Lazikani, AL Hopkins
Nature Reviews Drug Discovery 5 (12), 993-996, 2006
35402006
ChEMBL: a large-scale bioactivity database for drug discovery
A Gaulton, LJ Bellis, AP Bento, J Chambers, M Davies, A Hersey, Y Light, ...
Nucleic Acids Research 40, D1100-1107, 2012
24472012
The ChEMBL bioactivity database: an update
AP Bento, A Gaulton, A Hersey, LJ Bellis, J Chambers, M Davies, ...
Nucleic acids research 42 (D1), D1083-D1090, 2014
11312014
The genome of the blood fluke Schistosoma mansoni
M Berriman, BJ Haas, PT LoVerde, RA Wilson, GP Dillon, GC Cerqueira, ...
Nature 460 (7253), 352-358, 2009
10162009
A comprehensive map of molecular drug targets
R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ...
Nature reviews Drug discovery 16 (1), 19-34, 2017
8092017
The ChEMBL database in 2017
A Gaulton, A Hersey, M Nowotka, AP Bento, J Chambers, D Mendez, ...
Nucleic acids research 45 (D1), D945-D954, 2017
7732017
An atlas of genetic influences on human blood metabolites
SY Shin, EB Fauman, AK Petersen, J Krumsiek, R Santos, J Huang, ...
Nature Genetics 46, 543-540, 2014
6282014
HOMSTRAD: a database of protein structure alignments for homologous families
K Mizuguchi, CM Deane, TL Blundell, JP Overington
Protein Science 7 (11), 2469-2471, 1998
6081998
X-ray analysis of HIV-1 proteinase at 2.7A resolution confirms structural homology among retroviral enzymes
R Lapatto, T Blundell, A Hemmings, J Overington, A Wilderspin, S Wood, ...
Nature 342 (6247), 299-302, 1989
5201989
The promise and peril of chemical probes
CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ...
Nature chemical biology 11 (8), 536-541, 2015
4882015
Can we rationally design promiscuous drugs?
AL Hopkins, JS Mason, JP Overington
Current Opinion In Structural Biology 16 (1), 127-136, 2006
4882006
A community effort to assess and improve drug sensitivity prediction algorithms.
WK Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M ...
Nat Biotechnol. 32 (6), 2014
4552014
JOY: protein sequence-structure representation and analysis.
K Mizuguchi, CM Deane, TL Blundell, MS Johnson, JP Overington
Bioinformatics 14 (7), 617-623, 1998
4461998
Environment‐specific amino acid substitution tables: Tertiary templates and prediction of protein folds
J Overington, D Donnelly, MS Johnson, A Šali, TL Blundell
Protein Science 1 (2), 216-226, 1992
3701992
Derivation of rules for comparative protein modeling from a database of protein structure alignments
A Šali, JP Overington
Protein Science 3 (9), 1582-1596, 1994
3631994
Probing the links between in vitro potency, ADMET and physicochemical parameters
MP Gleeson, A Hersey, D Montanari, J Overington
Nature reviews Drug discovery 10 (3), 197-208, 2011
3622011
A Structural Basis for Sequence Comparisons: An Evaluation of Scoring Methodologies
MS Johnson, JP Overington
Journal of Molecular Biology 233 (4), 716-738, 1993
3591993
Genomic-scale prioritization of drug targets: the TDR Targets database
F Agüero, B Al-Lazikani, M Aslett, M Berriman, FS Buckner, RK Campbell, ...
Nature reviews Drug discovery 7 (11), 900-907, 2008
2982008
Tertiary structural constraints on protein evolutionary diversity: templates, key residues and structure prediction
J Overington, MS Johnson, A Šali, TL Blundell
Proceedings of the Royal Society of London. Series B: Biological Sciences …, 1990
2841990
PSICQUIC and PSISCORE: accessing and scoring molecular interactions
B Aranda, H Blankenburg, S Kerrien, FSL Brinkman, A Ceol, E Chautard, ...
Nature Methods 8 (7), 528-529, 2011
2572011
The system can't perform the operation now. Try again later.
Articles 1–20